Peptide Comparison
MOTS-cvsPancragen
A remarkable 16-amino-acid peptide encoded by your mitochondrial DNA that acts as an 'exercise mimetic'—boosting metabolism, improving insulin sensitivity, and helping your cells adapt to metabolic stress just like a good workout would.
Tetrapeptide bioregulator (Lys-Glu-Asp-Trp) that binds ACCT sequences in pancreatic gene promoters with 3-fold greater affinity than related peptides, stimulates beta-cell differentiation through Pdx1/Pax6/NGN3 transcription factor activation, and corrects impaired glucose tolerance in primates more physiologically than glimepiride
At a Glance
Quick
comparison
Dose Range
MOTS-c
10–10 mg
Pancragen
500–500 mcg
Frequency
MOTS-c
Once daily
Pancragen
Multiple times daily
Administration
MOTS-c
Subcutaneous injection
Pancragen
Intramuscular injection
Cycle Length
MOTS-c
4-6 weeks
Pancragen
8-12 weeks
Onset Speed
MOTS-c
Moderate (1-2 weeks)
Pancragen
Gradual (3-4 weeks)
Evidence Level
MOTS-c
Strong preclinical (extensive animal studies)
Pancragen
Limited human trials
Efficacy
Benefit
ratings
Metabolic Enhancement
Insulin Sensitivity
Mitochondrial Function
Blood Sugar Balance
Pancreas Protection
Metabolic Aging Support
Technical Data
Compound
specifications
MOTS-c
Molecular Formula
C101H152N28O22S2
Molecular Weight
2174.64 g/mol
Half-Life
Approximately 4-8 hours (estimated from preclinical data)
Bioavailability
High when injected subcutaneously
CAS Number
1627580-64-6
Pancragen
Molecular Formula
C26H36N6O9
Molecular Weight
576.6 g/mol
Half-Life
Short plasma half-life typical of tetrapeptides; biological effects persist for weeks through epigenetic modifications to pancreatic gene expression (primate studies showed partial effects 3 weeks post-treatment); metabolized to constituent amino acids
Bioavailability
Demonstrated efficacy with both oral (Pankragen-Forte capsules) and intramuscular routes; penetrates cell membranes and nuclear membranes to reach DNA promoter regions; oral bioavailability sufficient for clinical effects at 500 mcg doses
CAS Number
Not definitively assigned
Protocols
Dosing
tiers
MOTS-c
Pancragen
Applications
Best
suited for
MOTS-c
Metabolic Health Optimizers
If you're looking to improve how your body handles glucose and energy, MOTS-c directly targets these systems. It's like giving your cells a metabolic tune-up, helping them respond better to insulin and process sugar more efficiently—key factors for long-term health.
Those Seeking Exercise-Like Benefits
Nicknamed an 'exercise mimetic,' MOTS-c activates many of the same pathways that get turned on during physical activity. While it's not a replacement for actual exercise, it may help enhance the benefits you get from working out or provide some metabolic support when exercise is limited.
Weight Management Seekers
Animal studies show impressive prevention of diet-induced obesity. While human data is still emerging, MOTS-c's effects on fat metabolism and insulin sensitivity suggest potential benefits for those working on healthy weight management alongside diet and exercise.
Healthy Aging Enthusiasts
MOTS-c levels naturally decline with age, which may contribute to age-related metabolic problems. Supplementing may help restore more youthful metabolic function, supporting the body's ability to regulate energy and maintain muscle mass as we get older.
Pancragen
Supporting pancreatic function and glucose metabolism in aging individuals with prediabetic tendencies
Pancragen is particularly well-suited for individuals focused on supporting pancreatic function and glucose metabolism in aging individuals with prediabetic tendencies. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Geroprotective pancreatic support to maintain beta-cell differentiation and insulin production
Pancragen is particularly well-suited for individuals focused on geroprotective pancreatic support to maintain beta-cell differentiation and insulin production. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Comprehensive Khavinson bioregulator protocols targeting metabolic aging
Pancragen is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols targeting metabolic aging. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Adjunctive metabolic support alongside lifestyle interventions for age-related glucose intolerance
Pancragen is particularly well-suited for individuals focused on adjunctive metabolic support alongside lifestyle interventions for age-related glucose intolerance. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Safety Profile
Side
effects
MOTS-c
Common
- Injection site redness
- Mild fatigue
- Mild headache
Uncommon
- Changes in appetite
- Mild hypoglycemia symptoms
Serious
- Allergic reaction
Pancragen
Common
- Injection site reaction
- Mild fatigue
- Mild headache
- Minor digestive changes
Uncommon
- Mild hypoglycemia
Serious
- No documented serious adverse effects
Research Status
Safety
& evidence
MOTS-c
Evidence Level
Strong preclinical (extensive animal studies)
FDA Status
Research compound
Safety Overview
MOTS-c has shown an excellent safety profile in preclinical studies, with extensive animal research demonstrating beneficial effects without significant adverse events. The peptide is naturally produced by your own mitochondria, which suggests inherent compatibility with human biology. However, human clinical trial data is still limited, so caution is warranted. Most reported experiences involve minimal side effects, primarily mild injection site reactions.
Contraindications
- xPregnancy or planning to become pregnant
- xCurrently breastfeeding
- xActive cancer or history of cancer
- xKnown allergy to peptide components
- xChildren and adolescents
Pancragen
Evidence Level
Limited human trials
FDA Status
Research compound
Safety Overview
Pancragen shows favorable safety profile in preclinical toxicology studies with no serious adverse events at therapeutic doses. As a multi-peptide complex derived from pancreatic tissue, potential allergenicity risk exists in porcine-sensitive individuals. Gastrointestinal tolerance is excellent when taken orally. Limited human clinical data; primarily used in clinical practice in Central/Eastern Europe with reported safety in observational studies.
Contraindications
- xKnown hypersensitivity to peptide bioregulators or constituent amino acids (lysine, glutamic acid, aspartic acid, tryptophan)
- xPregnancy and breastfeeding — insufficient reproductive safety data
- xActive hypoglycemia or insulin-secreting tumors (insulinoma) — Pancragen's beta-cell stimulating effects may exacerbate hypoglycemia
- xConcurrent use of sulfonylureas without medical supervision — potential for additive hypoglycemic effects
Decision Guide
Which is
right for you?
Choose MOTS-c if...
- Metabolic health optimization
- Insulin sensitivity improvement
- Weight management support
- Mitochondrial function enhancement
Choose Pancragen if...
- Supporting pancreatic function and glucose metabolism in aging individuals with prediabetic tendencies
- Geroprotective pancreatic support to maintain beta-cell differentiation and insulin production
- Comprehensive Khavinson bioregulator protocols targeting metabolic aging
- Adjunctive metabolic support alongside lifestyle interventions for age-related glucose intolerance